Stock-Based Awards (Tables)

3 Months Ended

Mar. 31, 2025

Share-Based Payment Arrangement [Abstract]

Valuation Assumptions of Stock Options Granted

The assumptions that the Company used to determine the grant-date fair value of the stock options granted to employees and directors during the three months ended March 31, 2024 were as follows, presented on a weighted average basis:

	Three Months Ended March 31,
	2024
Risk-free interest rate		4.3	%
Expected term (in years)		5.5
Expected volatility		105.7	%
Expected dividend rate		0	%

Summary of Stock Option Activity

The following table summarizes the Company’s stock option activity since January 1, 2025:

	Number of Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at January 1, 2025		3,169,468		$	5.41		7.0	$	1,605
Exercised		(21,533	)		1.05		—		18
Forfeited/Canceled		(59,310	)		2.73		—		—
Expired		(8,043	)		85.03		—		—
Outstanding at March 31, 2025		3,080,582		$	5.28		6.7	$	913
Options exercisable at March 31, 2025		2,040,403		$	6.54		5.4	$	862
Options vested and expected to vest at March 31, 2025		3,040,624		$	5.32		6.7	$	910
Options exercisable at December 31, 2024		2,059,025		$	6.79		5.6	$	1,524
Options vested and expected to vest at December 31, 2024		3,120,812		$	5.45		7.0	$	1,600

There were no stock options granted in the three months ended March 31, 2025. The weighted average grant-date fair value of stock options granted during the three months ended March 31, 2024 was

Summary of Stock Based Compensation Expense

	Three Months Ended March 31,
	2025		2024
Research and development expenses	$	64	$	39
General and administrative expenses		200		111
Total stock-based compensation expense	$	264	$	150